amiodarone has been researched along with Venous Thromboembolism in 2 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Two weeks after amiodarone initiation (200 mg/d) hemoptysis occurred and computed tomography revealed unilateral pulmonary infiltrates with ground-glass opacities limited to the lower lobe of the left lung." | 7.81 | [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease]. ( Elikowski, W; Małek, M; Skowroński, M; Skrzywanek, P; Wróblewski, D; Zawilska, K, 2015) |
| " Two weeks after amiodarone initiation (200 mg/d) hemoptysis occurred and computed tomography revealed unilateral pulmonary infiltrates with ground-glass opacities limited to the lower lobe of the left lung." | 3.81 | [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease]. ( Elikowski, W; Małek, M; Skowroński, M; Skrzywanek, P; Wróblewski, D; Zawilska, K, 2015) |
| "Several key reports from the American Heart Association meeting, held in Orlando (FL, USA) in November 2011, are presented related to anti-thrombotic therapy in acute coronary syndrome and the use of dronedarone in permanent atrial fibrillation is discussed in this brief (and selective) overview of this meeting." | 3.78 | Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. ( Lip, GY; Shantsila, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elikowski, W | 1 |
| Małek, M | 1 |
| Skowroński, M | 1 |
| Wróblewski, D | 1 |
| Skrzywanek, P | 1 |
| Zawilska, K | 1 |
| Shantsila, A | 1 |
| Lip, GY | 1 |
2 other studies available for amiodarone and Venous Thromboembolism
| Article | Year |
|---|---|
[Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchiectasis; Drug Therapy, Combina | 2015 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagula | 2012 |